ADC Therapeutics Sees Continued Decrease In Total Operating Expenses In FY23 And FY24 As Compared to FY22; Expected Cash Runway Into Middle of 2025
ADC Therapeutics预计,与22财年相比,23财年和24财年的总运营支出将继续减少;预计现金流将持续到2025年中期
ADC Therapeutics Sees Continued Decrease In Total Operating Expenses In FY23 And FY24 As Compared to FY22; Expected Cash Runway Into Middle of 2025
ADC Therapeutics预计,与22财年相比,23财年和24财年的总运营支出将继续减少;预计现金流将持续到2025年中期
使用浏览器的分享功能,分享给你的好友吧